The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | OPB-11077 for newly diagnosed and R/R AML: Phase Ib update
Lindsay Wilde, MD, Thomas Jefferson University, Philadelphia, PA, discusses the results of the Phase Ib dose-escalating study (NCT03063944) evaluating the safety and efficacy of OPB-111077, a novel mitochondrial electron transport inhibitor, in addition to a venetoclax plus decitabine regimen in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML). Although the efficacy number are small, two out of nine patients achieved complete remission, where three patients died due to disease progression. OPB-111077 was generally well tolerated, with no dose-limiting toxicity observed. The most common adverse effects (AE) grade ≥3 were febrile neutropenia in 56% of patients, and muscle weakness in 11% of patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
